# A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

> **NCT04560998** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 792 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Peripheral Arterial Disease

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo (semaglutide)

## Key facts

- **NCT ID:** NCT04560998
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2024-06-05
- **Final completion:** 2024-07-12
- **Target enrollment:** 792 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04560998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04560998, "A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04560998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*